Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2025-12-25 @ 2:49 AM
NCT ID:
NCT00623233
Eligibility Criteria:
Inclusion Criteria:
* Must be female and greater than or equal to 18 yrs of age
* Participants must have confirmed cancer with measurable or evaluable, locally recurrent or metastatic disease.
* Participants must have received a taxane as neo-adjuvant and/or adjuvant therapy
* Participants may have received prior hormone therapy for locally recurrent or metastatic disease
Exclusion Criteria:
* Participants with breast cancer overexpressing Human Epidermal growth factor Receptor 2 (HER2) gene amplification
* Prior chemotherapy or targeted therapy for metastatic breast cancer
* Prior treatment with gemcitabine, trastuzumab, lapatinib or bevacizumab in any setting
* History of, or active brain mets
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to treatment, or anticipation of need for major surgical procedure during course of study
* Prior history of high blood pressure crisis
* Have a serious, nonhealing wound, ulcer, or bone fracture
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT00623233
Study Brief:
Protocol Section:
NCT00623233